ashibio

Executive Summary

āshibio is a clinical-stage biotechnology company developing first-in-class antibody therapies for rare bone and connective tissue disorders with high unmet medical need. The company's pipeline targets novel pathways such as MMP9 and FZD receptors for indications including fibrodysplasia ossificans progressiva (FOP) and osteopetrosis. With a focus on repurposing and developing monoclonal antibodies, āshibio aims to prevent or slow disease progression in these debilitating conditions. Founded in 2018 and based in San Diego, the company is privately held and has not disclosed total funding or valuation. Despite limited public information, its approach addresses critical gaps in rare disease treatment, positioning it for potential value inflection as clinical data emerge.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 Data Readout for FOP Candidate (MMP9 Antibody)45% success
• Q2 2027IND Filing for Osteopetrosis Program (FZD Antibody)60% success
• H1 2027Partnership or Licensing Deal for Pipeline Asset50% success